AZD-3409, with the CAS number 345915-10-8, is a chemical compound that has been investigated primarily for its potential therapeutic applications, particularly in the context of cancer treatment. It is classified as a small molecule inhibitor, specifically targeting certain pathways involved in tumor growth and proliferation. AZD-3409 is known to interact with specific proteins or enzymes that play a crucial role in cellular signaling, which can lead to the inhibition of cancer cell growth. The compound's structure includes functional groups that contribute to its biological activity and solubility properties. In preclinical studies, AZD-3409 has shown promise in modulating tumor responses, although its efficacy and safety profiles are subject to ongoing research. As with many investigational drugs, its pharmacokinetics, metabolism, and potential side effects are critical areas of study to determine its viability as a therapeutic agent. Overall, AZD-3409 represents a significant focus within the realm of targeted cancer therapies.

AZD-3409

345915-10-8: AZD-3409, with the CAS number 345915-10-8, is a chemical compound that has been investigated primarily for its potential therapeutic applications, particularly in the context of cancer treatment. It is classified as a small molecule inhibitor, specifically targeting certain pathways involved in tumor growth and proliferation. AZD-3409 is known to interact with specific proteins or enzymes that play a crucial role in cellular signaling, which can lead to the inhibition of cancer cell growth. The compound's structure includes functional groups that contribute to its biological activity and solubility properties. In preclinical studies, AZD-3409 has shown promise in modulating tumor responses, although its efficacy and safety profiles are subject to ongoing research. As with many investigational drugs, its pharmacokinetics, metabolism, and potential side effects are critical areas of study to determine its viability as a therapeutic agent. Overall, AZD-3409 represents a significant focus within the realm of targeted cancer therapies.

AZD 3409

AZD-3409 is a more potent prenyl transferase inhibitor than lonafarnib with varied IC(50) in cells, acting on gefitinib-resistant breast cancer.

CAS 345915-10-8

AZD-3409

AZD 3409

Ref: 3D-FA158499

AZD-3409

Ref: TM-T69403